In last trading session, Athersys, Inc. (NASDAQ:ATHX) saw 2,134,815 shares changing hands with its beta currently measuring -1.66. Company’s recent per share price level of $1.72 trading at $0.04 or 2.08% at ring of the bell on the day assigns it a market valuation of $370.22 Million. That closing price of ATHX’s stock is at a discount of -108.72% from its 52-week high price of $3.59 and is indicating a premium of 11.05% from its 52-week low price of $1.53. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 3.13 Million shares which gives us an average trading volume of 3.3 Million if we extend that period to 3-months.
For Athersys, Inc. (ATHX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.7. Splitting up the data highlights that, out of 4 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 4 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.09 in the current quarter.
Athersys, Inc. (NASDAQ:ATHX) trade information
Upright in the green during last session for gaining 2.08%, in the last five days ATHX remained trading in the green while hitting it’s week-highest on Friday, Apr 09 when the stock touched $1.9 price level, adding 9.47% to its value on the day. Athersys, Inc.’s shares saw a change of -1.71% in year-to-date performance and have moved -9.95% in past 5-day. Athersys, Inc. (NASDAQ:ATHX) showed a performance of -14.85% in past 30-days. Number of shares sold short was 26.04 Million shares which calculate 7.89 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $5.25 to the stock, which implies a rise of 205.23% to its current value. Analysts have been projecting $4 as a low price target for the stock while placing it at a high target of $7. It follows that stock’s current price would jump +306.98% in reaching the projected high whereas dropping to the targeted low would mean a loss of 132.56% for stock’s current value.
Athersys, Inc. (ATHX) estimates and forecasts
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $420Million for the same. And 3 analysts are in estimates of company making revenue of $420Million in the next quarter that will end on June 01, 2021.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -16% during past 5 years. In 2021, company’s earnings growth rate is likely to be around -43% while estimates for its earnings growth in next 5 years are of 0%
Athersys, Inc. (NASDAQ:ATHX)’s Major holders
Insiders are in possession of 8.73% of company’s total shares while institution are holding 25.48% percent of that, with stock having share float percentage of 27.92%. Investors also watch the number of corporate investors in a company very closely, which is 185 institutions for Athersys, Inc. that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at ATHX for having 13.71 Million shares of worth $24Million. And as of December 30, 2020, it was holding 6.37% of the company’s outstanding shares.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The second largest institutional holder is Vanguard Group, Inc. (The), which was holding about 10.16 Million shares on December 30, 2020. The number of shares represents firm’s hold over 4.72% of outstanding shares, having a total worth of $17.78 Million.
On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of March 30, 2021, the former fund manager was holding 9069121 shares of worth $16.32 Million or 4.21% of the total outstanding shares. The later fund manager was in possession of 5.67 Million shares on December 30, 2020, making its stake of worth around $9.92 Million in the company or a holder of 2.63% of company’s stock.